Chinese pharmaceutical companies are facing a critical talent shortage as they seek to expand into the U.S. market, according to a report by Inside Retail Asia. Drugmakers say finding executives with global regulatory and commercialization experience has become a major obstacle to overseas growth.
The shortage spans key roles including regulatory affairs specialists familiar with U.S. Food and Drug Administration requirements, as well as marketing and sales leaders who can navigate the complex American healthcare system. Many Chinese firms have invested heavily in R&D but lack the human capital to bring drugs to Western markets.
Industry analysts note that the talent gap could slow China's ambitions to become a global pharmaceutical player. Without experienced executives, Chinese drugmakers may struggle to compete with established multinationals and may face delays in obtaining approvals and building commercial infrastructure abroad.